High risk — avoid this combination unless there is no good alternative.
Higher rates of myopathy (muscle pain, weakness), elevated liver enzymes, and rare but serious rhabdomyolysis (which can cause kidney failure). No therapeutic gain to justify the added risk.
Why this happens (mechanism)
Atorvastatin (Lipitor) and rosuvastatin (Crestor) are both HMG-CoA reductase inhibitors — they share an identical mechanism. Combining them gives essentially no extra LDL lowering but doubles exposure to muscle and liver toxicity.
What to monitor
- Unexplained muscle pain, tenderness, or weakness — especially proximal (thighs, shoulders)
- Dark, cola-colored urine (sign of rhabdomyolysis)
- ALT/AST liver enzymes
- Creatine kinase (CK) if muscle symptoms appear
Dose adjustment
Do not combine. Choose the higher-potency single statin titrated to LDL goal. If maximally-tolerated statin monotherapy is insufficient, add a non-statin (ezetimibe or a PCSK9 inhibitor) instead.
Safer alternatives to consider
Doubling the dose of a single statin lowers LDL by another ~6%; safer than dual statin therapy.
Different mechanism — blocks cholesterol absorption — adds LDL lowering without overlapping toxicity.
Powerful LDL lowering for high-risk patients who can't tolerate statin escalation.
Always discuss alternatives with your prescriber before making any change. The right choice depends on your other medications, conditions, and what is working for you today.